Skip to main content
. 2016 Sep 29;11(9):e0163296. doi: 10.1371/journal.pone.0163296

Fig 4.

Fig 4

Indirect estimates from randomized clinical trials and estimates from observational studies with their corresponding 95% confidence intervals for (A) positive effect sizes and (B) negative effect sizes of the outcomes of interest reported as odds ratios between patients with relapsing remitting multiple sclerosis receiving natalizumab and those receiving fingolimod.